Sugi Predict

Sugi Predict / Compounds / SCHEMBL514089

SCHEMBL514089

SCHEMBL514089

COC(=O)Nc1ccccc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.68
▸ ALDH1A1 P00352 3/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ POLB P06746 3/20 0.60
▸ TUBB4A P04350 1/20 0.60
▸ TUBB P07437 1/20 0.60
▸ TUBA3C P0DPH7 1/20 0.60
▸ TUBA1B P68363 1/20 0.60
▸ TUBA4A P68366 1/20 0.60
▸ TUBB4B P68371 1/20 0.60
▸ TUBB3 Q13509 1/20 0.60
▸ TUBB2A Q13885 1/20 0.60
▸ TUBB8 Q3ZCM7 1/20 0.60
▸ TUBA3E Q6PEY2 1/20 0.60
▸ TUBA1A Q71U36 1/20 0.60
▸ TUBA1C Q9BQE3 1/20 0.60
▸ TUBB6 Q9BUF5 1/20 0.60
▸ TUBB2B Q9BVA1 1/20 0.60
▸ TUBB1 Q9H4B7 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514088 0.87 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL6850954 0.86 ALDH1A1 (0.71) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL31040567 0.86 POLB (0.77) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL4554983 0.86 POLB (0.77) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL11659356 0.85 HPGD (0.64) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL171580 0.84 KMT2A (0.70) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL2093160 0.84 ALDH1A1 (0.62) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL30356246 0.84 KMT2A (0.70) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL2755842 0.84 ALDH1A1 (0.77) KMT2AL3MBTL1ALDH1A1SMN1; SMN2POLB
SCHEMBL2093161 0.84 SMN1; SMN2 (0.65) KMT2AALDH1A1SMN1; SMN2POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7081481-B2 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY (US) 2006-07-25 — — US claimed
US-20040102521-A1 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY 2004-05-27 — — US claimed
EP-1289940-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP claimed
WO-2001092213-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2001-12-06 — — WO claimed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 — — WO disclosed
CN-114591202-A Ferulic acid derivative, preparation method and application 西安医学院 2022-06-07 — — CN disclosed
US-20210323913-A1 SIGMA RECEPTOR BINDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-10-21 — — US disclosed
US-20210300903-A1 SIGMA RECEPTOR BINDERS UNIV TEXAS (US) 2021-09-30 — — US disclosed
EP-3508473-B1 METHOD FOR PRODUCING CARBAMIC ACID ESTER AIST (JP) 2021-05-26 — — EP disclosed
US-10752579-B2 Production method of carbamic acid ester NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2020-08-25 — — US disclosed
EP-3508473-A1 METHOD FOR PRODUCING CARBAMIC ACID ESTER National Institute of Advanced Industrial Science and Technology (JP) 2019-07-10 — — EP disclosed
US-20190185420-A1 PRODUCTION METHOD OF CARBAMIC ACID ESTER NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2019-06-20 — — US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 — — US disclosed
US-7081481-B2 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY (US) 2006-07-25 — — US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 — — EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 — — WO disclosed
US-20040102521-A1 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY 2004-05-27 — — US disclosed
EP-1289940-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP disclosed
WO-2001092213-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2001-12-06 — — WO disclosed
US-4600797-A NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP BAYER AKTIENGESELLSCHAFT (DE) 1986-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 KMT2A 1865/4885L3MBTL1 4435/4885ALDH1A1 750/4885
US-20040102521-A1 Excitatory amino acid receptor modulators GRM1, GRM2, GRIN1 KMT2A 1257/4885L3MBTL1 2983/4885ALDH1A1 1907/4885
US-20210323913-A1 SIGMA RECEPTOR BINDERS SIGMAR1, OPRK1, OPRL1 KMT2A 3025/4885L3MBTL1 881/4885ALDH1A1 431/4885
US-20190185420-A1 PRODUCTION METHOD OF CARBAMIC ACID ESTER CA2, CA7, CA4 KMT2A 243/4885L3MBTL1 3678/4885ALDH1A1 3215/4885
US-10752579-B2 Production method of carbamic acid ester CA2, CA7, CA4 KMT2A 243/4885L3MBTL1 3678/4885ALDH1A1 3215/4885
US-20210300903-A1 SIGMA RECEPTOR BINDERS SIGMAR1, OPRK1, OPRL1 KMT2A 2607/4885L3MBTL1 1380/4885ALDH1A1 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.